http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg#Head http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg#assertion http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg#provenance http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg#pubinfo http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg#assertion http://purl.obolibrary.org/obo/DOID_0060058 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_0060058 http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00531 http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg#association http://www.w3.org/2000/01/rdf-schema#label cyclophosphamide for injection is an alkylating drug indicated for treatment of malignant diseases 1 1 minimal change nephrotic syndrome in pediatric patients 1 2 limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established cyclophosphamide for injection is indicated for the treatment of malignant lymphomas stages iii and iv of the ann arbor staging system hodgkin s disease lymphocytic lymphoma nodular or diffuse mixed cell type lymphoma histiocytic lymphoma burkitt s lymphoma multiple myeloma leukemias chronic lymphocytic leukemia chronic granulocytic leukemia it is usually ineffective in acute blastic crisis acute myelogenous and monocytic leukemia acute lymphoblastic stem cell leukemia cyclophosphamide for injection given during remission is effective in prolonging its duration mycosis fungoides advanced disease neuroblastoma disseminated disease adenocarcinoma of the ovary retinoblastoma carcinoma of the breast cyclophosphamide for injection although effective alone in susceptible malignancies is more frequently used concurrently or sequentially with other antineoplastic drugs cyclophosphamide for injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00531 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg#provenance http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg#pubinfo http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg#sig http://purl.org/nanopub/x/hasSignature N1LNiRe6tZFKbX0s7TkR6RrzoGXTT+GCZmo09bA25k/w1l13l6NjkQPWbJ5Uz24EyBjyN24FRhZzTU614z5NGTzBW+31HKv0seOe58ygRbTDeYoS5Oy9YbQfSrzMe7nJ/Soi4wO8CK3HLqGtIas4ZzU5tqMOwGCnp8xjMyyJG3k= http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg http://purl.org/dc/terms/created 2021-07-03T15:49:00.931+02:00 http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAQNZDgxZN1agyH1qzoWtKRfyHNksmrgYP9IE8sFdBWhg https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs